Regenxbio (NASDAQ:RGNX) Azioni

REGENXBIO INC

Regenxbio

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Regenxbio Inc

News

Management

GTBP

GT Biopharma Appoints Michael Breen As CEO For Two-Year Term

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) reported first-quarter financial results after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/b45206388/palantir-reports-q1-2025-revenue-growth-of-39-yy-u-s-revenue-growth-of-55-yy-raises-fy-2025-revenu">of the report</a>.
Q1 Earnings: Palantir reported first-quarter revenue of $883.86 million, beating <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a>&nbsp;of $862.83 million. The company reported first-quarter adjusted earnings of 13 cents per share, in line with analyst estimates.
Palantir has now met or exceeded analyst estimates for revenue and earnings in seven straight quarters, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a> data.
Total revenue was up 39% year-over-year as U.S. revenue grew 55% year-over-year to $628 million. U.S. Commercial revenue grew 71% year-over-year to $255 million and U.S. Government revenue climbed 45% year-over-year to $373 million.
Palantir's customer count grew 39% year-over-year and 8% on a quarter-over-quarter basis. The company said it closed 139 deals worth over $1 million during the quarter and 51 deals worth at least $5 million. Palantir generated $310 million in cash from operations and $370 million in adjusted free cash flow in the quarter.&nbsp;
Palantir ended the quarter with $5.4 billion of cash, cash equivalents and short-term U.S. treasury securities.
&#8220;Our Rule of 40 score increased to&nbsp;83%&nbsp;in the last quarter, once again breaking the metric. We are in the middle of a tectonic shift in the adoption of our software,&#8221; said&nbsp;Alex Karp, co-founder and CEO of Palantir.
&#8220;We are delivering the operating system for the modern enterprise in the era of AI. Consequently, we are raising our full-year&nbsp;guidance&nbsp;for total revenue growth to&nbsp;36%&nbsp;and our&nbsp;guidance&nbsp;for U.S. commercial revenue growth to&nbsp;68%.&#8221;
See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45202080/stocks-pause-gains-as-treasury-yields-rise-whats-driving-markets-monday">Stocks Pause Gains As Treasury Yields Rise: What&#8217;s Driving Markets Monday?</a>
Outlook: Palantir expects second-quarter revenue to be in the range of $934 million to $938 million versus estimates of $899.12 million.
The company also raised its full-year guidance. Palantir expects full-year 2025 revenue of $3.89 billion to $3.90 billion, up from prior guidance of $3.74 billion to $3.76 billion. Analysts were anticipating full-year revenue of $3.75 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Palantir raised guidance for full-year U.S. commercial revenue, full-year adjusted income from operations and adjusted free cash flow. The company now expects full-year adjusted free cash flow of $1.6 billion to $1.8 billion, up from prior guidance of $1.5 billion to $1.7 billion.
Finally, Palantir continued to guide for positive GAAP operating income and net income in each quarter of 2025.
&#8220;This is a level of surging and ferocious growth that would be spectacular for a company a tenth of our size. At this scale, however, our ascent is, we believe, unparalleled,&#8221; Karp said in a letter to shareholders. 
Palantir executives will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET.
PLTR Price Action: <a href="https://www.benzinga.com/quote/PLTR" target="_blank" rel="noreferrer noopener">Palantir shares </a>were up approximately 64% year-to-date heading into Monday&#8217;s report. The stock was down 9.23% in after-hours, trading at $112.35 at the time of publication Monday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45203793/datadogs-ai-cloud-migration-expanding-product-adoption-drive-analyst-confidence-despite-growth-volatility-concerns">Datadog&#8217;s AI, Cloud Migration, Expanding Product Adoption Drive Analyst Confidence Despite Growth Volatility Concerns</a></li>
</ul>
Image: <a href="https://www.shutterstock.com/g/PoetraRH">Poetra.RH</a>/Shutterstock.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; WATCH LIVE: Palantir Technologies Q1 2025 Earnings Call &#x7C; $PLTR" width="500" height="281" src="https://www.youtube.com/embed/WgOqogXV_w4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Earnings

Guidance

After-Hours Center

Movers

Tech

PLTR

Palantir Q1 Earnings: Revenue Beat, EPS In Line, Customer Count Up 39%, Company Raises Guidance Citing 'Surging And Ferocious Growth'

Refinanced Existing Credit Facility Drawing $150 Million at Close with $100 Million of Strategic Incremental Capacity
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evolus.com%2Four-culture%2F&amp;esheet=54248377&amp;newsitemid=20250505216119&amp;lan=en-US&amp;anchor=Evolus%2C+Inc.&amp;index=1&amp;md5=d86edc3e18acb91ab674d69a87838519">Evolus, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million credit facility with funds managed by Pharmakon Advisors, LP.
Highlights of the new facility include:
<ul>
<li>Lowered Interest Rate: Reduced borrowing cost by 350 basis points (bps) based on current interest rates. The facility will mature five years from the funding date. Interest will be paid quarterly using the 3-month SOFR plus 5.00% per annum.</li>
<li>Improved Structure &amp; Financial Flexibility: Converted from an amortizing structure to a bullet maturity payment, with significantly reduced pre-payment fees, avoided any pre-payment fees from the existing facility, and additional consideration of 1% of the drawn value for the new facility, making it a cost-effective agreement.</li>
<li>Increased Capital Availability: Added $100 Million of discretionary incremental capacity with a senior secured term loan of up to $250 million in three tranches, with $150 million being drawn upon the execution of the agreement. At its discretion, Evolus may draw up to two additional tranches of $50 million each through December 31, 2026. These second and third tranches are available with no additional performance conditions or financial covenants.</li>
</ul>

EOLS

Evolus Replaces Existing $125M Credit Agreement With New $250M Credit Facility With Funds Managed By Pharmakon Advisors

TG Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) on Monday reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">consensus of 17 cents</a>.
The company reported sales of $120.86 million, up from $63.47 million a year ago, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45190356/tg-therapeutics-reports-first-quarter-2025-financial-results-and-raises-briumvi-full-year-revenue-" rel="noreferrer noopener">consensus of $118.43 million</a>.
Michael S. Weiss, the Company&#8217;s Chairman and Chief Executive Officer, stated, &#8220;2025 is off to a strong start, and I&#8217;m incredibly proud of the progress made thus far. Our performance in the first quarter, including BRIUMVI&#8217;s $119.7 million in U.S. net sales, demonstrates the growing confidence in our treatment and the increasing adoption by healthcare providers. This momentum, combined with the positive feedback we&#8217;re hearing from both patients and clinicians, reinforces our belief that we can achieve our long-term goal of BRIUMVI becoming the number one prescribed anti-CD20 treatment based on dynamic market share.&#8221; 
&#8220;In addition to our ongoing BRIUMVI commercialization efforts, we are continuing to invest in innovation, including simplifying the BRIUMVI treatment regimen, advancing subcutaneous BRIUMVI, and developing azer-cel for progressive MS,&#8221; Weiss added.
Briumvi sales reached $119.7 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44439613/stock-of-the-day-tg-therapeutics-breaks-out-may-head-higher" rel="noreferrer noopener">Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher</a>
The company said it presented five-year data from the open-label extension study of the ULTIMATE I &amp; II Phase 3 trials evaluating Briumvi in adult patients with relapsing forms of multiple sclerosis (RMS).
<ul>
<li>The data demonstrated that 92% of patients were free from disability progression after five years of treatment, an annualized relapse rate of 0.02 during year 5 of treatment (equivalent to one relapse occurring every fifty years of patient treatment), and an overall safety profile that remained consistent, with no new safety signals emerging over 5 years of continuous treatment and no observed cases of progressive multifocal leukoencephalopathy (PML) to date.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45147899/biogen-beats-q1-earnings-expectations-as-two-newcomer-drug-sales-spike-avoids-tariff-impact" rel="noreferrer noopener">Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact</a>
The company also presented data from the ENHANCE Phase 3b trial evaluating alternative dosing strategies for Briumvi in patients with RMS, which demonstrated that:
<ul>
<li>A single 600 mg Briumvi infusion on Day 1 was well tolerated in individuals with RMS regardless of prior treatment or B-cell depletion status.</li>
<li>Rapid 30-minute Briumvi infusions were well tolerated in patients with RMS.</li>
</ul>
Guidance: TG Therapeutics raised Briumvi&#8217;s U.S. net product revenue target to $560 million for fiscal 2025 from $525 million in prior guidance.
<ul>
<li>The company raised the total global revenue target to $575 million from prior guidance of $540 million.</li>
</ul>
Briumvi&#8217;s U.S. net product revenue is expected to be $135 million in the second quarter of 2025.
Price Action: TGTX stock was down 13.2% at $37.68 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45199066/berkshire-hathaway-stock-falls-following-buffetts-retirement-as-ceo" target="_blank" rel="noreferrer noopener">Berkshire Hathaway Stock Falls Following Buffett&#8217;s Retirement As CEO</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Trading Ideas

General

TGTX

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show

Offerings

MAIA

MAIA Biotechnology Announces $1.08M Private Placement Of 719,999 Shares At $1.50/Share

Valaris Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) ("Valaris" or the "Company") announced today that it has agreed to sell jackup VALARIS 247 to BW Energy ("BWE") for cash proceeds of approximately $108 million. This sale is expected to close in the second half of 2025, subject to customary closing conditions. As part of the sales agreement, BWE will be restricted from using the rig outside of BWE-owned or affiliated properties for the rig's expected remaining useful life.

Valaris Agrees To Sell Jackup VALARIS 247 To BW Energy For Cash Proceeds Of About $108M

Solesence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLSN#NASDAQ">SLSN</a>) reported $14.63 million in sales this quarter. This is a 48.21 percent increase over sales of $9.87 million the same period last year.

SLSN

Solesence Q1 EPS $0.00 Down From $0.02 YoY; Sales $14.63M Up From $9.87M YoY

New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) raises FY2025 Adj EPS guidance from $3.05-$3.20 to $3.15-$3.30 vs $3.15 analyst estimate..

New Jersey Resources Raises FY2025 Adj EPS Guidance from $3.05-$3.20 to $3.15-$3.30 vs $3.15 Est

New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) reported quarterly earnings of $1.78 per share which beat the analyst consensus estimate of $1.62 by 9.88 percent. This is a 26.24 percent increase over earnings of $1.41 per share from the same period last year. The company reported quarterly sales of $913.03 million which beat the analyst consensus estimate of $732.00 million by 24.73 percent. This is a 38.78 percent increase over sales of $657.91 million the same period last year.

Earnings Beats

New Jersey Resources Q2 Adj. EPS $1.78 Beats $1.62 Estimate, Sales $913.03M Beat $732.00M Estimate

Accel Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACEL#NYSE">ACEL</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.20 by 15 percent. This is unchanged from the same period last year. The company reported quarterly sales of $323.91 million which beat the analyst consensus estimate of $318.75 million by 1.62 percent. This is a 7.32 percent increase over sales of $301.82 million the same period last year.

ACEL

Accel Entertainment Q1 Adj. EPS $0.23 Beats $0.20 Estimate, Sales $323.91M Beat $318.75M Estimate

Dividends

Cabot Corporation Board Increases Dividend From $0.43 to $0.45

JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 180.95 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $776.00 million which beat the analyst consensus estimate of $767.97 million by 1.05 percent. This is a 19.09 percent decrease over sales of $959.10 million the same period last year.

JELD

JELD-WEN Holding Q1 Adj. EPS $(0.17) Beats $(0.19) Estimate, Sales $776.00M Beat $767.97M Estimate

Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) affirms FY2025 Adj EPS guidance from $3.95-$4.15 to $3.95-$4.15 vs $4.06 analyst estimate. Raises FY2025 sales outlook from $2.85 billion-$2.90 billion to $2.87 billion-$2.92 billion vs $2.88 billion estimate.

BFAM

Bright Horizons Family Affirms FY2025 Adj EPS Guidance of $3.95-$4.15 vs $4.06 Est; Raises FY2025 Sales Guidance from $2.85B-$2.90B to $2.87B-$2.92B vs $2.88B Est

Crawford (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.20 by 5 percent. This is a 61.54 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $323.34 million which beat the analyst consensus estimate of $321.00 million by 0.73 percent. This is a 3.28 percent increase over sales of $313.07 million the same period last year.

CRD/A

Crawford Q1 Adj. EPS $0.21 Beats $0.20 Estimate, Sales $323.34M Beat $321.00M Estimate

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) lowers FY2025 sales outlook from $302.00 million-$307.00 million to $297.50 million-$303.50 million vs $304.62 million estimate.

HSTM

HealthStream Lowers FY2025 Sales Guidance from $302.00M-$307.00M to $297.50M-$303.50M vs $304.62M Est

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.16 by 12.5 percent. This is a 17.65 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $73.48 million which missed the analyst consensus estimate of $74.93 million by 1.93 percent. This is a 1.00 percent increase over sales of $72.76 million the same period last year.

Earnings Misses

HealthStream Q1 GAAP EPS $0.14 Misses $0.16 Estimate, Sales $73.48M Miss $74.93M Estimate

Boot Barn Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) (the "Company" or "Boot Barn") today announced that its Board of Directors has appointed John Hazen as Chief Executive Officer ("CEO"), effective May 5, 2025. Mr. Hazen had been serving as the Company's Interim Chief Executive Officer since November 2024.

BOOT

Boot Barn Holdings Appoints John Hazen As CEO, Effective May 5, 2025

Tidewater (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) affirms FY2025 sales outlook from $1.32 billion-$1.38 billion to $1.32 billion-$1.38 billion vs $1.34 billion estimate.

Tidewater Affirms FY2025 Sales Guidance of $1.32B-$1.38B vs $1.34B Est

Cabot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBT#NYSE">CBT</a>) lowers FY2025 Adj EPS guidance from $7.40-$7.80 to $7.15-$7.50 vs $7.52 analyst estimate..

Cabot Lowers FY2025 Adj EPS Guidance from $7.40-$7.80 to $7.15-$7.50 vs $7.52 Est

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) affirms FY2025 FFO guidance from $1.43-$1.46 to $1.43-$1.46 vs $1.46 analyst estimate..

Comments

Regenxbio

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO